News

We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.

Expert views

Overcoming Oligonucleotide Manufacturing Challenges

24 Mar 2023 - The Oligonucleotide CMO industry faces a number of challenges – Demand out pacing capacity for manufacturing, available expertise, high solvent and waste usage to name a […]

Read more
Expert views

Chemical strategies in extending half-lives of therapeutic peptides

24 Mar 2023 - Therapeutic peptides have been proven to be very effective in treating critical human diseases. Their number on the pharmaceutical market has significantly increased over the past […]

Read more
Media releases

PolyPeptide publishes invitation to the annual General Meeting 2023

22 Mar 2023 - Baar, 22 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (the “Company”), published today the […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023

14 Mar 2023 - Baar, 14 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its results for […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

CEO of PolyPeptide resigns

30 Jan 2023 - Baar, 30 January 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the resignation by […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide signs significant commercial agreement

19 Dec 2022 - Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide provides market update

2 Dec 2022 - Baar, 2 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today provided a market update. […]

Read more
Business news

FluoGuide reaches milestone with FG001 for phase III clinical supply

9 Nov 2022 - “We are thankful for the opportunity to work with FluoGuide on the highly innovative FG001 project and congratulate the whole team for reaching this milestone.”

Read more
Expert views

From 10 grams to several hundred – A case study in peptide GMP process development

17 Oct 2022 - Presentation from TIDES digital week, September 2022, by Niall McLoughlin, PhD, Development Project Chemist at PolyPeptide Group.[…]

Read more